Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Virological Suppression in HIV Positive Patients Involved in a Novel Standardized Adherence Protocol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03517358
Recruitment Status : Recruiting
First Posted : May 7, 2018
Last Update Posted : May 1, 2019
Sponsor:
Information provided by (Responsible Party):
University of California, Davis

Brief Summary:
This study will look at virologically suppression of patients with HIV who receive pharmacist or case management care.

Condition or disease Intervention/treatment Phase
Hiv Other: Service of care Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Virological Suppression in HIV Positive Patients Involved in a Novel, Standardized Adherence Protocol
Actual Study Start Date : January 1, 2018
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : December 31, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Active Comparator: Pharmacy
service of care: pharmacy
Other: Service of care
Subjects will be receiving care from case management or clinical pharmacy.

Active Comparator: Case management
service of care: case management
Other: Service of care
Subjects will be receiving care from case management or clinical pharmacy.




Primary Outcome Measures :
  1. Percentage of virological suppression [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients with a baseline viral load > 200 copies/ml
  • Patients who agree to program enrollment
  • Patients ≥ 18 years of age

Exclusion Criteria:

  • Pregnant women
  • Adults unable to consent
  • Prisoners

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03517358


Locations
Layout table for location information
United States, California
One Community Health Recruiting
Sacramento, California, United States, 95831
Contact: Anne T Le    832-605-6971    atrle@ucdavis.edu   
Sponsors and Collaborators
University of California, Davis

Layout table for additonal information
Responsible Party: University of California, Davis
ClinicalTrials.gov Identifier: NCT03517358     History of Changes
Other Study ID Numbers: 1150661
First Posted: May 7, 2018    Key Record Dates
Last Update Posted: May 1, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Seropositivity
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases